Claritas HealthTech Announces Spin-Off of Claritas NucMed Technologies Ltd to Lead Global Delivery of its Suite of Software Solutions in Nuclear Medicine
2024年7月29日 - 8:30PM
Claritas HealthTech (Claritas) a healthcare
technology company specializing in advanced medical image
enhancement, reconstruction, signal processing, and AI solutions
for the medical industry
, announces it is spinning
off its nuclear medicine division into a separate company, named,
Claritas NucMed Technologies Ltd (Claritas
NucMed). Claritas NucMed, established and registered in the UK,
will focus on the global commercialization, delivery and deployment
of its nuclear medicine suite of software solutions for PET and
SPECT.
Claritas, headquartered in London, is a leader
in developing cutting-edge image processing and AI diagnostic tools
across various modalities ranging from radiology and nuclear
medicine to endoscopy, dermatology and ophthalmology. With several
years of R&D and collaboration with its clinical partners, the
company has developed pioneering technology for precision
enhancement, reconstruction, lesion detection and quantification of
isotope uptake in PET an SPECT imaging.
Chetan Baxi, CEO of Claritas commented, “The
establishment of Claritas NucMed Technologies Ltd, strengthens our
focus, and enables us to execute on our strategic plans for
delivery and deployment of our solutions in nuclear medicine. The
company has focused significant R&D efforts on achieving
solutions that provide accurate results, to aid the clinician in
achieving improved outcomes for the patient in this area. The
establishment of Claritas NucMed will enable us to capitalize on
growth opportunities in this segment.”
With the increasing prevalence and screening of
different types of cancers, the rising demand for PET-CT (Positron
Emission Tomography – Computed Tomography) imaging results in
delays and long waiting times. Further, demand for PET imaging is
increasing exponentially, going beyond its traditional use in
detecting cancer to other conditions such as cardiac, vascular,
neurological and treatment monitoring. The Claritas
iPET™ enhancement capability is significant as it can be
used for reducing scan times and reducing isotope dosage required
while yielding diagnostic quality images. Claritas
iPETcertum™, extends this capability, aiding
clinicians with accurate and automatic lesion detection and
quantification, based on clinician-defined uptake parameters.
Single Photon Emission Computed Tomography
(SPECT), myocardial perfusion imaging (MPI) is one of the most
common procedures in performed in cardiology. Reducing radiation
exposure to patients is a global goal. Claritas
iSPECTcardiac™, is a software solution that
enables reducing scan time and/or contrast dosage by 50% in SPECT
imaging.
For inquiries or further information, please contact:
Devika Dutt
d.d@claritasco.com
About Claritas
HealthTech Limited
Claritas conducts research and development in
the fields of image enhancement, machine vision and artificial
intelligence (“AI”) with a focus on medical image processing and
AI-assisted interpretation and diagnostics. Claritas aims to
transform the diagnostics industry with powerful and effective
software products created using image enhancement and AI
technology, to enable and assist doctors in medical diagnostics.
Claritas AI-assisted diagnostic tools are fully compliant with
HIPAA, PDPA and GDPR requirements. For more information, please
visit www.claritashealthtech.com.